TY - JOUR AU - Nelson, Valerie AU - Rademaker, Alfred AU - Kaklamani, Virginia PY - 2012 TI - Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant JF - Chinese Clinical Oncology; Vol 2, No 1 (March 10, 2013): Chinese Clinical Oncology Y2 - 2012 KW - N2 - Endocrine therapy is the cornerstone of any treatment plan for endocrine-responsive breast cancer in both the adjuvant and metastatic settings (1). In the metastatic setting in post-menopausal patients aromatase inhibitors (AIs; anastrozole, exemestane, letrozole) are standard therapies, shown to demonstrate improved progression-free survival (PFS) and a favorable adverse effect (AE) profile compared to other endocrine agents such as tamoxifen (2,3). UR - https://cco.amegroups.org/article/view/1111